Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Gastrointestinal Neoplasms × trastuzumab deruxtecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4 Neoplasm Metastasis 3 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Pancreatic Neoplasms 1 Neoplasms 1 Gastrointestinal Neoplasms 1 Adenocarcinoma 1

Interventions

trastuzumab deruxtecan 1 repotrectinib 1 pralsetinib 1 encorafenib 1 Standard of Care 1 Oxaliplatin 1 Levoleucovorin 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Cetuximab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Daiichi Sankyo

Phase 2 Completed

233 enrolled 26 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡